Today's Date: June 3, 2023
Statement from Minister Hutchings on progress in support of rural Canadians   •   BURGERFI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bu   •   SENTINELONE ALERT: Bragar Eagel & Squire, P.C. is Investigating SentinelOne, Inc. on Behalf of SentinelOne Stockholders and   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DZS Inc. (DZSI) on Behalf of Investors   •   Rapid Dose Announces Proposed Private Placement Financing   •   The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve   •   CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors   •   The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit   •   Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Funko, Inc. with Losses of $100,000 to Contact the Firm   •   HESAI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Hesai   •   Hilton brings back exclusive pop-up hotel experience 'Hilton on the Green' to the 2023 RBC Canadian Open   •   UNice Celebrates LGBTQ Pride Month   •   ETHNIC CONFLICTS IN NIGERIA: UNMASKING THE PUPPET MASTERS   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   FNKO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Funko, Inc. Investors with Substantial Losses Have Opp   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award
Bookmark and Share

New Data Demonstrates vMap’s Use Associated with Significantly Improved Outcomes in Atrial Fibrillation Treatment Study

SAN DIEGO , March 21 /Businesswire/ - Vektor Medical, developer of the world’s only technology to rapidly map arrhythmias using just 12-lead ECG data, today announced that use of the vMap® arrhythmia mapping system during complex atrial fibrillation (AF) ablation was associated with significantly improved freedom from atrial arrhythmias compared with standard-of-care pulmonary vein isolation. The results will be presented at the Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium on Saturday, March 25, in La Jolla, California.

“Using vMap, we were able to efficiently identify AF source locations and then successfully ablate target sites, resulting in a significantly higher success rate than in the control group,” stated David Krummen, Professor of Clinical Medicine at University of California San Diego, co-founder and inventor for Vektor Medical. “Traditionally, ablation success rates for the complex AF patients included in this study have been disappointing, and mechanistic insights which may guide ablation to atrial fibrillation-sustaining sites are desperately needed. While additional studies will be needed to validate the findings in a larger population, the high rate of arrhythmia-free survival seen in the study arm at six months is extremely encouraging.”

In a novel feasibility study, patients who received targeted AF-driver ablation, guided by the vMap arrhythmia mapping system, as well as PVI had significantly higher rates of freedom from AF and AT than the control patients undergoing pulmonary vein isolation alone at a median follow-up of six months. The findings add to the growing body of evidence that demonstrates vMap’s exciting potential to improve treatment of atrial fibrillation and a range of other arrhythmias. For the study, complex atrial fibrillation ablation was defined as patients with persistent AF, recurrent AF after prior ablation, and atrial fibrillation associated with a second atrial arrhythmia.

The study included a treatment arm of 15 AF patients who received successful PVI and AF driver site ablation guided by vMap. The control arm consisted of 54 persistent and paroxysmal AF patients who had successful PVI. The study found that additional AF driver site ablation guided by the vMap system was associated with an 87.5% freedom from all atrial arrhythmias compared with the control arm’s 58.0% arrhythmia-free survival (p=0.043). Additional multicenter studies are planned to further validate the study results.

“I absolutely believe that treatment for AF is not one size fits all and these results are another reminder that we, as electrophysiologists, can continue to do better in our treatment plan for atrial fibrillation,” said Dr. Alborz Hassankhani, MD, PhD, an electrophysiologist not associated with the study. “While for many the standard of care may be pulmonary vein isolation, these results suggest that targeted driver-site ablation may help deliver the superior results our patients deserve. The fact that we see so many recurrences following ablation tells me that there is something fundamental missing in our approach to this disease. vMap seems to provide a guide to a more individualized approach. The results speak for themselves.”

About vMap®

vMap® is a next-generation, FDA-cleared technology that enables rapid and non-invasive mapping of arrhythmia sources for focal or fibrillation-type arrhythmias in all four chambers of the heart, with 97.3% accuracy. vMap utilizes advanced machine learning techniques and proprietary computational models to extract valuable information from a standard 12-lead ECG, providing functional insights into the location of arrhythmia sources. The goal of vMap is to improve medicine by optimizing our understanding of arrhythmias and improving ablations by accurately identifying the sources of those arrhythmias.

About Vektor Medical

San Diego-based Vektor Medical, is committed to enhancing arrhythmia care for the millions of individuals affected by atrial fibrillation and other arrhythmias. Through its non-invasive cardiac arrhythmia technology, vMap, the company aims to enhance the success rate of first-pass ablation, reduce the risks associated with invasive mapping, and shorten procedure times. These advancements are expected to result in better outcomes for patients and a decrease in healthcare costs related to ablation procedures.

STORY TAGS: United States, North America, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, California, Product/Service,


White House Live Stream
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News